nodes	percent_of_prediction	percent_of_DWPC	metapath
Fidaxomicin—ABCB1—Mitoxantrone—lymphatic system cancer	0.262	0.475	CbGbCtD
Fidaxomicin—ABCB1—Vincristine—lymphatic system cancer	0.18	0.327	CbGbCtD
Fidaxomicin—ABCB1—Methotrexate—lymphatic system cancer	0.109	0.198	CbGbCtD
Fidaxomicin—Metabolic acidosis—Teniposide—lymphatic system cancer	0.0329	0.0733	CcSEcCtD
Fidaxomicin—Metabolic acidosis—Fludarabine—lymphatic system cancer	0.0289	0.0644	CcSEcCtD
Fidaxomicin—Megacolon—Methotrexate—lymphatic system cancer	0.0206	0.046	CcSEcCtD
Fidaxomicin—Platelet count decreased—Mitoxantrone—lymphatic system cancer	0.0114	0.0255	CcSEcCtD
Fidaxomicin—Intestinal obstruction—Vincristine—lymphatic system cancer	0.0102	0.0228	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Fludarabine—lymphatic system cancer	0.00829	0.0185	CcSEcCtD
Fidaxomicin—Neutropenia—Teniposide—lymphatic system cancer	0.00762	0.017	CcSEcCtD
Fidaxomicin—Dysphagia—Fludarabine—lymphatic system cancer	0.00717	0.016	CcSEcCtD
Fidaxomicin—Neutropenia—Fludarabine—lymphatic system cancer	0.0067	0.0149	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00652	0.0145	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00646	0.0144	CcSEcCtD
Fidaxomicin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00611	0.0136	CcSEcCtD
Fidaxomicin—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00547	0.0122	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.00531	0.0118	CcSEcCtD
Fidaxomicin—Anaemia—Teniposide—lymphatic system cancer	0.00525	0.0117	CcSEcCtD
Fidaxomicin—Malnutrition—Fludarabine—lymphatic system cancer	0.00499	0.0111	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.00493	0.011	CcSEcCtD
Fidaxomicin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00463	0.0103	CcSEcCtD
Fidaxomicin—Anaemia—Fludarabine—lymphatic system cancer	0.00461	0.0103	CcSEcCtD
Fidaxomicin—Dysphagia—Carmustine—lymphatic system cancer	0.00459	0.0102	CcSEcCtD
Fidaxomicin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00445	0.00992	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00435	0.0097	CcSEcCtD
Fidaxomicin—Neutropenia—Carmustine—lymphatic system cancer	0.00429	0.00956	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00414	0.00922	CcSEcCtD
Fidaxomicin—Dyspnoea—Teniposide—lymphatic system cancer	0.00413	0.00921	CcSEcCtD
Fidaxomicin—Neutropenia—Vincristine—lymphatic system cancer	0.00409	0.00913	CcSEcCtD
Fidaxomicin—Decreased appetite—Teniposide—lymphatic system cancer	0.00403	0.00898	CcSEcCtD
Fidaxomicin—Vomiting—Mechlorethamine—lymphatic system cancer	0.004	0.00891	CcSEcCtD
Fidaxomicin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.004	0.00891	CcSEcCtD
Fidaxomicin—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00399	0.00889	CcSEcCtD
Fidaxomicin—Rash—Mechlorethamine—lymphatic system cancer	0.00397	0.00884	CcSEcCtD
Fidaxomicin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00396	0.00883	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00385	0.00857	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00379	0.00845	CcSEcCtD
Fidaxomicin—Nausea—Mechlorethamine—lymphatic system cancer	0.00374	0.00833	CcSEcCtD
Fidaxomicin—Abdominal pain—Teniposide—lymphatic system cancer	0.00367	0.00817	CcSEcCtD
Fidaxomicin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00363	0.0081	CcSEcCtD
Fidaxomicin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00359	0.008	CcSEcCtD
Fidaxomicin—Decreased appetite—Fludarabine—lymphatic system cancer	0.00354	0.0079	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00352	0.00784	CcSEcCtD
Fidaxomicin—Constipation—Fludarabine—lymphatic system cancer	0.00348	0.00777	CcSEcCtD
Fidaxomicin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00342	0.00761	CcSEcCtD
Fidaxomicin—Anaemia—Bleomycin—lymphatic system cancer	0.00338	0.00754	CcSEcCtD
Fidaxomicin—Pruritus—Teniposide—lymphatic system cancer	0.00328	0.00731	CcSEcCtD
Fidaxomicin—Malnutrition—Carmustine—lymphatic system cancer	0.0032	0.00712	CcSEcCtD
Fidaxomicin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.003	0.00669	CcSEcCtD
Fidaxomicin—Anaemia—Carmustine—lymphatic system cancer	0.00295	0.00658	CcSEcCtD
Fidaxomicin—Vomiting—Teniposide—lymphatic system cancer	0.00295	0.00657	CcSEcCtD
Fidaxomicin—Rash—Teniposide—lymphatic system cancer	0.00292	0.00652	CcSEcCtD
Fidaxomicin—Dermatitis—Teniposide—lymphatic system cancer	0.00292	0.00651	CcSEcCtD
Fidaxomicin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00291	0.00648	CcSEcCtD
Fidaxomicin—Headache—Teniposide—lymphatic system cancer	0.0029	0.00647	CcSEcCtD
Fidaxomicin—Pruritus—Fludarabine—lymphatic system cancer	0.00288	0.00643	CcSEcCtD
Fidaxomicin—Anaemia—Vincristine—lymphatic system cancer	0.00282	0.00628	CcSEcCtD
Fidaxomicin—Nausea—Teniposide—lymphatic system cancer	0.00275	0.00614	CcSEcCtD
Fidaxomicin—Anaemia—Mitoxantrone—lymphatic system cancer	0.00275	0.00612	CcSEcCtD
Fidaxomicin—Dyspnoea—Bleomycin—lymphatic system cancer	0.00266	0.00594	CcSEcCtD
Fidaxomicin—Decreased appetite—Bleomycin—lymphatic system cancer	0.0026	0.00579	CcSEcCtD
Fidaxomicin—Vomiting—Fludarabine—lymphatic system cancer	0.00259	0.00578	CcSEcCtD
Fidaxomicin—Rash—Fludarabine—lymphatic system cancer	0.00257	0.00573	CcSEcCtD
Fidaxomicin—Dermatitis—Fludarabine—lymphatic system cancer	0.00257	0.00572	CcSEcCtD
Fidaxomicin—Headache—Fludarabine—lymphatic system cancer	0.00255	0.00569	CcSEcCtD
Fidaxomicin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00244	0.00544	CcSEcCtD
Fidaxomicin—Nausea—Fludarabine—lymphatic system cancer	0.00242	0.0054	CcSEcCtD
Fidaxomicin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00235	0.00525	CcSEcCtD
Fidaxomicin—Dyspnoea—Carmustine—lymphatic system cancer	0.00233	0.00518	CcSEcCtD
Fidaxomicin—Decreased appetite—Carmustine—lymphatic system cancer	0.00227	0.00505	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00225	0.00502	CcSEcCtD
Fidaxomicin—Constipation—Carmustine—lymphatic system cancer	0.00223	0.00497	CcSEcCtD
Fidaxomicin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0022	0.00491	CcSEcCtD
Fidaxomicin—Decreased appetite—Vincristine—lymphatic system cancer	0.00216	0.00482	CcSEcCtD
Fidaxomicin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00216	0.00482	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00215	0.00479	CcSEcCtD
Fidaxomicin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00213	0.00476	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00213	0.00475	CcSEcCtD
Fidaxomicin—Constipation—Vincristine—lymphatic system cancer	0.00213	0.00475	CcSEcCtD
Fidaxomicin—Pruritus—Bleomycin—lymphatic system cancer	0.00211	0.00471	CcSEcCtD
Fidaxomicin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00211	0.0047	CcSEcCtD
Fidaxomicin—Constipation—Mitoxantrone—lymphatic system cancer	0.00207	0.00462	CcSEcCtD
Fidaxomicin—Abdominal pain—Carmustine—lymphatic system cancer	0.00206	0.0046	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00204	0.00454	CcSEcCtD
Fidaxomicin—Neutropenia—Methotrexate—lymphatic system cancer	0.00199	0.00443	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00198	0.00442	CcSEcCtD
Fidaxomicin—Abdominal pain—Vincristine—lymphatic system cancer	0.00197	0.00439	CcSEcCtD
Fidaxomicin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00192	0.00428	CcSEcCtD
Fidaxomicin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00192	0.00427	CcSEcCtD
Fidaxomicin—Vomiting—Bleomycin—lymphatic system cancer	0.0019	0.00423	CcSEcCtD
Fidaxomicin—Rash—Bleomycin—lymphatic system cancer	0.00188	0.0042	CcSEcCtD
Fidaxomicin—Dermatitis—Bleomycin—lymphatic system cancer	0.00188	0.0042	CcSEcCtD
Fidaxomicin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00183	0.00409	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00179	0.00399	CcSEcCtD
Fidaxomicin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00179	0.00398	CcSEcCtD
Fidaxomicin—Nausea—Bleomycin—lymphatic system cancer	0.00177	0.00396	CcSEcCtD
Fidaxomicin—Dizziness—Carmustine—lymphatic system cancer	0.00172	0.00384	CcSEcCtD
Fidaxomicin—Vomiting—Carmustine—lymphatic system cancer	0.00166	0.0037	CcSEcCtD
Fidaxomicin—Dizziness—Vincristine—lymphatic system cancer	0.00165	0.00367	CcSEcCtD
Fidaxomicin—Rash—Carmustine—lymphatic system cancer	0.00164	0.00367	CcSEcCtD
Fidaxomicin—Dermatitis—Carmustine—lymphatic system cancer	0.00164	0.00366	CcSEcCtD
Fidaxomicin—Headache—Carmustine—lymphatic system cancer	0.00163	0.00364	CcSEcCtD
Fidaxomicin—Vomiting—Vincristine—lymphatic system cancer	0.00158	0.00353	CcSEcCtD
Fidaxomicin—Rash—Vincristine—lymphatic system cancer	0.00157	0.0035	CcSEcCtD
Fidaxomicin—Dermatitis—Vincristine—lymphatic system cancer	0.00157	0.0035	CcSEcCtD
Fidaxomicin—Headache—Vincristine—lymphatic system cancer	0.00156	0.00348	CcSEcCtD
Fidaxomicin—Nausea—Carmustine—lymphatic system cancer	0.00155	0.00345	CcSEcCtD
Fidaxomicin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00154	0.00344	CcSEcCtD
Fidaxomicin—Immune system disorder—Methotrexate—lymphatic system cancer	0.00154	0.00342	CcSEcCtD
Fidaxomicin—Rash—Mitoxantrone—lymphatic system cancer	0.00153	0.00341	CcSEcCtD
Fidaxomicin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00153	0.0034	CcSEcCtD
Fidaxomicin—Headache—Mitoxantrone—lymphatic system cancer	0.00152	0.00339	CcSEcCtD
Fidaxomicin—Malnutrition—Methotrexate—lymphatic system cancer	0.00148	0.0033	CcSEcCtD
Fidaxomicin—Nausea—Vincristine—lymphatic system cancer	0.00148	0.0033	CcSEcCtD
Fidaxomicin—Dysgeusia—Methotrexate—lymphatic system cancer	0.00145	0.00323	CcSEcCtD
Fidaxomicin—Nausea—Mitoxantrone—lymphatic system cancer	0.00144	0.00321	CcSEcCtD
Fidaxomicin—Anaemia—Methotrexate—lymphatic system cancer	0.00137	0.00305	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00125	0.00279	CcSEcCtD
Fidaxomicin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00118	0.00264	CcSEcCtD
Fidaxomicin—Skin disorder—Methotrexate—lymphatic system cancer	0.00117	0.00262	CcSEcCtD
Fidaxomicin—Dyspnoea—Methotrexate—lymphatic system cancer	0.00108	0.0024	CcSEcCtD
Fidaxomicin—Dyspepsia—Methotrexate—lymphatic system cancer	0.00106	0.00237	CcSEcCtD
Fidaxomicin—Decreased appetite—Methotrexate—lymphatic system cancer	0.00105	0.00234	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00104	0.00232	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000988	0.0022	CcSEcCtD
Fidaxomicin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000955	0.00213	CcSEcCtD
Fidaxomicin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00089	0.00198	CcSEcCtD
Fidaxomicin—Pruritus—Methotrexate—lymphatic system cancer	0.000855	0.00191	CcSEcCtD
Fidaxomicin—Dizziness—Methotrexate—lymphatic system cancer	0.000799	0.00178	CcSEcCtD
Fidaxomicin—Vomiting—Methotrexate—lymphatic system cancer	0.000768	0.00171	CcSEcCtD
Fidaxomicin—Rash—Methotrexate—lymphatic system cancer	0.000762	0.0017	CcSEcCtD
Fidaxomicin—Dermatitis—Methotrexate—lymphatic system cancer	0.000761	0.0017	CcSEcCtD
Fidaxomicin—Headache—Methotrexate—lymphatic system cancer	0.000757	0.00169	CcSEcCtD
Fidaxomicin—Nausea—Methotrexate—lymphatic system cancer	0.000718	0.0016	CcSEcCtD
